I n 1936, Studley noted that patients who had lost 20% or more of their body weight before surgery for peptic ulcer disease had a significantly higher mortality than patients with the same condition but more modest weight losses. 1 Other observational studies subsequently confirmed this association between malnutrition (defined by weight loss, reduced anthropometric measurements, hypoalbuminemia, and/or loss of delayed cutaneous hypersensitivity) and an adverse clinical outcome in patients with a variety of diseases. [2] [3] [4] Even healthy individuals who are deprived of adequate nutrients for a long enough period of time will develop adverse clinical events because of malnutrition. 5 Therefore, it seems reasonable that providing nutritional support to malnourished patients would have beneficial effects. Years of research were directed at developing solutions and technology whereby total nutrient requirements could be safely administered intravenously. 6 In the 1960s, investigators at the University of Pennsylvania combined central venous access with newly developed nutrient solutions, 7 and the modern era of parenteral nutrition was born.
Parenteral nutrition was widely accepted and implemented. Subsequently, the use of enteral nutrition and tube feeding also increased and became more sophisticated. Most patients received this nutritional support for days or weeks in the hospital; longer-term delivery was accomplished in home settings. Societies specializing in nutritional support were created throughout the world. The annual expenditure for nutritional support in the United States grew into billions of dollars. 8, 9 The rationale for using nutritional support is often the same whether the intervention is delivered orally, enterally, or parenterally. However, the objective of this technical review is only to assess the clinical efficacy of parenteral nutrition. Conclusions made regarding the efficacy of this form of nutritional support may not necessarily apply to enteral nutritional support. Physiologic differences are present when nutrients are delivered directly into the systemic circulation rather than into the intestine. For example, parenteral nutrition completely eliminates enteral stimulatory processes and the "first pass" of nutrients through the liver.
The best way to establish the efficacy of a clinical intervention is to demonstrate it in a randomized controlled trial (RCT). Therefore, we limited our analysis to data from RCTs that evaluated the efficacy of parenteral nutrition on one or more clinically important parameters of mortality, morbidity, duration of hospitalization, or cost. Whenever possible, we reviewed studies that compared the use of parenteral nutrition to no nutritional support. Because only limited data were available for some clinical conditions, other RCTs were also considered, including those that compared enteral with parenteral nutrition.
This review was prepared using the principles of systematic reviewing. A protocol was written in which a priori decisions were made regarding the literature search strategy and the planned analyses. Wherever possible, we used meta-analysis to make an estimate of the treatment effect of parenteral nutrition. Meta-analysis is a statistical technique that combines results from multiple studies. It provides 2 potential advantages over simply looking at individual trials: (1) it allows a more precise estimate of the magnitude of a treatment effect, and (2) it can increase the power to identify a treatment effect that is not apparent in smaller individual studies. However, no 2 trials are precisely the same, and the problem of adding "apples and oranges" is always present. This issue (heterogeneity) is always a consideration and potential limitation of meta-analysis.
Before beginning the formal review of over 100 RCTs, a cautionary statement must be made. The large majority of the RCTs failed to identify any benefit attributable to parenteral nutrition; some even found that parenteral nutrition was harmful. Virtually all of these trials excluded patients who were severely malnourished (defined by a large-percentage weight loss or a very low body mass 
Meta-Analysis
Inclusion criteria. Any RCT (including one only reported as an abstract) that met the following criteria was used in the meta-analyses:
1. The report explicitly stated that the patient groups were randomized. Quasi-randomized trials (allocation based on day of week, record number, or some other system whereby the group assignment was known by the investigator and/or subject before accession into the trial) were excluded. 2. The study compared treated patients (those receiving intravenous fluids containing a source of nitrogen [as amino acids or protein hydrolysate] and at least 10 kcal ⅐ kg Ϫ1 ⅐ day Ϫ1 of nonprotein calories) to control patients, who received no nutrient intake beyond that contained in ad libitum feedings and/or 5% (or in the case of neonatal trials, 10%) dextrose intravenously as maintenance fluid. 3. The study reported one or more outcomes of mortality, morbidity, duration of hospitalization, and/or cost.
Eighty-two trials met these criteria and became the database for the parenteral nutrition meta-analysis. 10 -111 Another 27 RCTs evaluated a form of intravenous nutrition in which nitrogen was infused along with an amount of calories that was inadequate to meet the daily requirement (Ͻ10 kcal ⅐ kg Ϫ1 ⅐ day Ϫ1 ). 28, 30, 98, [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] This form of intravenous nutrition, referred to as "protein-sparing therapy," was separately evaluated in a protein-sparing therapy meta-analysis.
For a variety of reasons, other RCTs were not included in these meta-analyses. These studies, as well as the reasons for exclusion, are listed in the Appendix.
Outcome assessment. Each identified RCT was categorized by clinical condition and reviewed for outcomes of mortality, total complications, infectious complications, duration of hospitalization, and cost. For each clinical condition itemized in Table 1 , data regarding disease-specific outcomes were also identified when available. Data from each RCT were abstracted twice, and differences were resolved by consensus.
When a report included more than 1 eligible treatment arm, each treatment group was compared with the common control group and considered to be a separate trial. When data were presented as the total number of events, rather than the number of patients who had that event, it was assumed that there was 1 event per patient. (If the number of events was greater than the number of patients, it was assumed that each patient had at least 1 such event.) When data were presented in graphic, rather than tabular, form, numerical data were estimated from the graph.
Some endpoints (e.g., mortality) have low occurrence rates; differences can only be detected if large numbers of patients are available. Other outcomes (e.g., duration of hospitalization) have low rates of reporting. To detect such effects of parenteral nutrition or protein sparing therapy, global meta-analyses of all the eligible trials were performed.
Meta-analysis was performed only when data were available from at least 3 trials. Thus, the calculations were performed only in the following sets of RCTs:
1. A global meta-analysis of all eligible trials (both parenteral nutrition and protein sparing) 2. Perioperative trials (both parenteral nutrition and protein-sparing therapy meta-analyses) 3. Oncologic therapy trials (cancer chemotherapy, radiation therapy, and bone marrow transplantation; only parenteral nutrition meta-analysis) 4. Alcoholic hepatitis trials (only protein-sparing therapy meta-analysis) 5. Low-birth-weight infants trials (only parenteral nutrition meta-analysis)
For dichotomous variables (mortality and morbidity events), each estimated effect is presented as the absolute risk difference (the difference between the incidence in the treated group and the incidence in the control group) and 95% confidence interval. A negative risk difference indicates that there is a decreased risk, and a positive one indicates that there is an increased risk associated with the treatment. A significant effect is present whenever a 95% confidence interval does not overlap 0. The number needed to treat to prevent (or cause) one outcome event is calculated by dividing 100 by the absolute risk difference. For example, if the risk difference for a particular complication were Ϫ5%, it would be necessary to treat 20 patients to prevent one such event. Similarly, if the risk difference were ϩ5%, treating 20 patients would result in one additional complication.
Duration of hospitalization is a continuous variable. These data are reported as weighted mean differences (a weighted average of the differences seen in each trial) and 95% confidence interval. A negative number represents a shorter duration in the treatment group. In these analyses, a significant effect is present when the 95% confidence interval does not overlap 0.
Because heterogeneity was anticipated, all of the metaanalyses were performed using a random effects model. The computer programs used were Revman 4.0.4 and Metaview 3.1 (Cochrane Collaboration, Oxford, England).
Subgroup analyses. For each of the outcomes in the parenteral nutrition meta-analysis, separate calculations were undertaken to assess the following factors:
1. Use or non-use of lipid in the parenteral nutrition formulation. Nutritional support was considered to include lipid if at least 15% of total nonprotein calories in the nutritional formulation were derived from lipid. Nonuse of lipid meant either that no lipid was provided or that only small amounts of lipid (Ͻ15% of the total nonprotein calories) were used periodically, usually to prevent essential fatty acid deficiency. 2. Presence or absence of malnutrition in the study population. A trial was considered to contain malnourished patients if at least 50% of the patients satisfied the investigators' definition of malnutrition at entry. A trial was considered not to contain malnourished patients if Ͻ50% of the patients satisfied this criterion. Malnutrition was variably defined in these trials, and those definitions ranged from modest weight loss alone to more profound weight loss, and/or hypoalbuminemia, and/or abnormalities in anthropometric measurements, or skin test reactivity. 3. Inclusion of only those trials that were reported in full paper form (i.e., not just as an abstract). 4. Inclusion of only those trials in which the nutritional therapy was provided for at least 7 days. 5. Inclusion of only those trials that reported outcome events as the number of affected patients (i.e., not just as total number of events). 6. Provision of parenteral nutrition only in the preoperative period, only in the postoperative period, or in both. 7. Provision of parenteral nutrition only for patients undergoing surgery for upper gastrointestinal cancer. (This subgroup analysis was the only one not determined a priori.) 8. Provision of parenteral nutrition for patients treated with chemotherapy, radiation therapy, or bone marrow transplantation.
We were unable to perform such subgroup analyses in the meta-analysis of protein-sparing therapy for the following reasons:
footnotes in this and subsequent tables include data from selected subgroup analyses.
Mortality. Parenteral nutrition did not influence mortality. The subgroup analyses did not alter the overall estimate.
Complications. There was no significant effect of parenteral nutrition on the total complication rate. Only 1 of the subgroup analyses identified a significant difference-in the trials in which lipid was not used, parenteral nutrition was associated with an increased total complication rate.
Parenteral nutrition was associated with a significant increase in the infectious complication rate; the absolute risk difference was ϩ5%. Parenteral nutrition resulted in 1 additional infection for every 20 patients who were treated. In almost every subgroup analysis, the estimates were positive (treatment associated with more infections), although the confidence intervals sometimes overlapped 0. Significant differences were observed in the trials in which lipid was not used, in which only nourished patients were included, in which parenteral nutrition was provided for at least 7 days, and in the trials reported as full papers.
This harmful effect was caused largely by the effect parenteral nutrition had in cancer patients receiving oncologic therapy. It was not observed when the perioperative or low-birth-weight clinical conditions were separately analyzed. Six other trials of parenteral nutrition provided data regarding infection rates. 96, 99, 100, 107, 109, 111 When these RCTs were combined, a treatment-related increase in the infection rate was also observed. This latter computation is displayed in Figure 1 . Rates of infectious complications in 6 trials not included in meta-analyses of perioperative, oncologic, or lowbirth-weight infants. In all 6 trials, the direction of the effect is positive (control group had better outcome). Abbreviations: Expt, treated group; Ctrl, control group; RD, risk difference; n, number with infection; N, number randomized to that arm; CI, confidence interval; df, degrees of freedom; Z, Z score for heterogeneity.
Duration of hospitalization. Parenteral nutrition had no major effect on duration of hospitalization, at least in the perioperative state. Using lipid in the nutritional infusion and only treating groups of nourished patients were the 2 factors significantly associated with reduced hospital stays of about 2 days. Nutritional infusions not including lipid and treatment of populations that included malnourished patients were the 2 factors significantly associated with prolonged durations of stay of about 5 days.
Cost. There were inadequate data to perform a meta-analysis regarding cost.
Summary and implications of the data. The problem of heterogeneity is most apparent in this global meta-analysis. At first consideration, it would not appear to make any sense to combine trials in so many disparate clinical conditions, even if the therapeutic intervention being tested was similar. We decided a priori to undertake this meta-analysis despite the heterogeneity of the trials because we believed that this would be the only way to identify a subtle effect of parenteral nutrition (e.g., on mortality). It was our intent to do a series of subgroup analyses to identify more precisely the circumstances under which effects were or were not present. We subjected 82 RCTs (containing over 4000 patients) to meta-analysis. The results indicated that, compared with standard therapy, parenteral nutrition did not improve survival, the total complication rate, or the length of hospitalization.
The meta-analysis showed that parenteral nutrition increased the infectious complication rates. In part, this was attributable to an adverse effect in cancer patients undergoing oncologic therapy. Such an adverse effect was not observed in perioperative patients or low-birthweight infants. However, the fact that this effect was also present when the other trials were combined indicates that the relationship between parenteral nutrition and an increased risk of infection is more generalizable.
Global Meta-analysis of Protein-Sparing Therapy
Trials. There were 27 trials that compared protein sparing to standard therapy. 28, 30, 98, [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] The results of the meta-analyses of this intervention are presented in Table 2 .
Mortality. Protein-sparing therapy did not affect survival.
Complications. Protein-sparing therapy had no effect on the total or infectious complication rates.
Duration of hospitalization. Data regarding the duration of hospitalization were available only in surgical trials. Protein-sparing therapy had no effect on this outcome.
Summary and implications of the data. This meta-analysis of 27 RCTs did not show any beneficial effect of protein-sparing therapy on mortality, morbidity, or duration of hospitalization. Most of these trials were conducted in perioperative patients or in patients with alcoholic hepatitis.
Perioperative Trials
Trials. The largest number of RCTs in both meta-analyses came from trials of patients treated before and/or after surgery. There were 41 such trials identified for the parenteral nutrition meta-analysis, 10 -52 and 20 RCTs evaluated protein-sparing therapy. 28, 30, [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] The largest RCT identified in this review was one of the protein-sparing therapy studies; it included 678 patients. 114 The estimated absolute risk differences for both parenteral nutrition and protein-sparing therapy are presented in Table 3 .
Mortality. Neither parenteral nutrition nor protein-sparing therapy affected postoperative mortality. The subgroup analyses did not identify any significant beneficial or harmful effects.
Postoperative complications. Parenteral nutrition had no significant effect on the various postoperative complication rates. However, the directions of the absolute risk differences were always negative (i.e., the effect tended to favor treatment).
A number of subgroup analyses were performed. Parenteral nutrition was associated with a significant reduction in total complications in the trials that excluded malnourished patients and in trials in which lipids were part of the nutritional formulation. When the trials were separated into those that provided only preoperative, 10 -21 only postoperative, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] or both preoperative and postoperative 40 -52 parenteral nutrition, no significant effect was observed, although the absolute risk differences tended to be slightly more favorable for treatment in the preoperative trials.
When only trials containing patients with upper gastrointestinal cancer were considered, the absolute risk differences were always negative. In this subgroup, parenteral nutrition significantly reduced the major complication rate.
Postoperative patients are given nothing by mouth for some period of time. To see if longer periods of therapy were important, we separately analyzed the subset of 13 postoperative trials in which the treatment groups were administered parenteral nutrition for more than 7 days (range, 8 -18 days) and the control group was not given any form of nutritional support. 22, 24, 29, 33, [37] [38] [39] [40] 47 One of these trials did allow fallback to parenteral nutrition, 24 but only after a complication occurred. The results of the meta-analysis of these trials are displayed in Table 4 . No significant effect of the nutritional intervention was observed.
Protein-sparing therapy had no effect on postoperative morbidity. The results from the large single trial 114 were the same as the estimates derived when all of the smaller RCTs were combined.
Duration of hospitalization. Parenteral nutrition had no effect on the duration of hospitalization of surgical patients.
Summary and implications of the data. Although parenteral nutrition was not shown to reduce postoperative complications with statistical certainty, almost all of the absolute risk differences were negative. Even if a true beneficial effect were to exist, it would not be dramatic. A small benefit must be weighed against the cost of the therapy. If we were to assume that parenteral nutrition reduces the total complication rate by 6% (Table 3) , more than 16 patients would need to be treated for at least 7 days each to prevent 1 adverse event. The use of parenteral nutrition would be economically justifiable only if these complications were very expensive. 131 In a meta-analysis evaluating the clinical efficacy of parenteral nutrition in critically ill and perioperative patients, Heyland et al. 132 concluded that studies using lipid-free infusions and those including malnourished patients (as defined by each investigator or, if not de- fined, by Ͼ10% weight loss) were more likely to show a benefit from parenteral nutrition. We could not confirm either of these observations. In fact, in our analysis perioperative patients who received lipids had better outcomes, and trials that evaluated only well-nourished patients were more likely to demonstrate a benefit of parenteral nutrition. The probable reason for this disagreement is that the 2 meta-analyses did not combine the same data. Heyland et al. included 26 RCTs. However, 3 of them were not in surgical patients. 99, 116, 133 Six of the remaining 23 were excluded from this analysis. 112-114,134 -136 Although the remaining 17 were included in our meta-analysis, we also included 24 others. 11,12,14,17-19,23,25,26,28,29,31-38,40,42,44 -46 The VA cooperative study suggested that severely malnourished patients (as defined by the Nutrition Risk Index 48 or the Subjective Global Assessment 4 ) may have benefitted from preoperative parenteral nutrition. 48 Although the differences did not achieve statistical significance, the rates of major postoperative complications were 20%-25% in severely malnourished patients given parenteral nutrition and 40%-50% in the nutritionally comparable controls. It is important to realize that this degree of malnutrition was not present in most or all of the patients enrolled in other trials. As such, our data are inadequate to confirm or refute this conclusion from the VA trial.
Muller et al. 17 suggested that parenteral nutrition was beneficial in patients with upper gastrointestinal malignancies. We combined the trials that only included patients with cancer of the stomach and/or esophagus. 13, 17, 25, 26, [37] [38] [39] For each of the analyses, the estimated absolute risk differences were negative (i.e., favoring treatment), and a significant benefit (estimated risk difference, 18%) was demonstrated for reduction of major complications. Treating 5.5 patients with parenteral nutrition for at least 7 days to prevent a major complication may be justifiable from the perspective of resource allocation. However, it should be remembered that this subgroup analysis was undertaken to validate the observation of Muller et al. When the data of Muller et al. were removed, no significant differences remained, although all of the risk differences still favored treatment.
It is unlikely that inadequate duration of treatment was responsible for the failure to demonstrate a more profound effect of parenteral nutrition. Most of the trials provided parenteral nutrition for at least a week; and when only those studies were considered, no benefit was observed. Even in the RCTs in which parenteral nutrition was provided postoperatively for more than 7 days, no effect of the intervention could be demonstrated.
A review of nutritional support, sponsored by the National Institutes of Health (NIH), the American Society for Parenteral and Enteral Nutrition (ASPEN), and the American Society for Clinical Nutrition (ASCN) was published in 1997 137 and included an evaluation of the influence of parenteral nutrition on clinical outcome in surgical patients. Pooling data separately from 13 RCTs that provided preoperative parenteral nutrition and 8 RCTs that provided it only postoperatively found that the preoperative intervention resulted in a 10% reduction in postoperative complications, but that postoperative treatment alone produced a 10% increase in the complication rate.
We examined this observation by considering separately the trials that used parenteral nutrition only in the preoperative period, only in the postoperative period, or during both periods. We did not find that preoperative therapy conferred significant benefits or that postoperative treatment was harmful. However, the absolute risk differences were somewhat more favorable in the preoperative studies.
Again, the likely reason for the disparate findings relates to the trials that were included or excluded in the 2 analyses. We reclassified 41, [43] [44] [45] [46] [47] [48] or excluded 134,136,138 -141 5 preoperative and 6 postoperative RCTs included in the NIH/ASPEN/ASCN review. In addition, we included 3 other preoperative 11, 12, 14, 19 and 20 other postoperative 23,25-39 trials in our analysis that were not included in the NIH/ASPEN/ASCN report. Of particular note, we excluded the largest published postoperative trial (300 patients) because the control group received 10% dextrose. 136 That study found a statistically significant increase in complications in the recipients of the parenteral nutrition and was a dominant factor in the NIH/ASPEN/ ASCN analysis.
Although protein-sparing therapy improves nitrogen balance, 28,30,112-116,118 -20,124 it does not affect mortality or morbidity when it is provided during the postoperative period. This dissociation between nutritional and clinical outcomes, observed in other trials of nutritional support, 142 underscores the importance of using clinical outcomes data rather than surrogate nutritional markers.
Oncologic Therapy
Trials. We identified 19 RCTs assessing parenteral nutrition in cancer patients receiving chemotherapy, 3 RCTs in cancer patients being treated with radiation therapy with or without concomitant chemotherapy, [87] [88] [89] [90] and 4 RCTs in patients undergoing bone marrow transplantation. [91] [92] [93] [94] [95] The results of this meta-analysis are summarized in Table 5 .
Mortality. There was no apparent effect of parenteral nutrition on mortality. When subgroup analyses were performed, none could be found in which there was an effect on survival.
Although Weisdorf et al. 94 reported that parenteral nutrition increased survival in patients undergoing bone marrow transplantation, we did not observe a significant survival difference when we combined the data from 4 RCTs assessing bone marrow transplantation. [91] [92] [93] [94] [95] However, the largest of the 4 RCTs 91 assessed the role of home parenteral nutrition after the patients were discharged. This is a different scenario than the one that was tested by Weisdorf et al. When the data from the other 3 were combined, there was a nonsignificant trend for the parenteral nutrition to improve mortality.
One RCT did assess the value of parenteral nutrition provided to patients with end-stage malignancies receiving no specific cancer therapy. 81, 82 The treated recipients lived significantly longer (46 days) than did the controls (7 days).
Complications. The use of parenteral nutrition resulted in an increased total complication rate. Parenteral nutrition also increased the incidence of infectious complications. A significant increased risk for both total and infectious complications was associated with parenteral nutrition in almost every subgroup evaluated in the subgroup analyses.
Tumor-response rate. The tumor-response rates (to chemotherapy in particular) were also adversely affected by the parenteral nutrition. All of the absolute risk differences in the subgroup analyses favored the control group, although these differences did not always achieve statistical significance.
Treatment toxicity. Parenteral nutrition did not appear to provide any benefit with regard to either bone marrow or gastrointestinal toxicity. No effect was observed in any of the subgroup analyses.
Summary and implications of the data. Parenteral nutrition does not alter survival in patients receiving radiation or chemotherapy. The data cannot exclude the possibility that in-hospital parenteral nutrition will favorably affect survival in patients undergoing bone marrow transplantation.
In all other aspects, the use of parenteral nutrition in cancer patients receiving chemotherapy, radiation therapy, or bone marrow transplantation was clearly associated with net harm. Parenteral nutrition was associated with increases in total and infectious complication rates. In addition, parenteral nutrition was associated with an impaired tumor response to chemotherapy, which may be related to exogenous nutrients stimulating tumor growth. 14, [143] [144] [145] [146] Liver Disease Trials. Two trials comparing parenteral nutrition 96, 97 and 5 trials comparing protein-sparing therapy [125] [126] [127] [128] [129] to standard treatment were conducted in patients with alcoholic hepatitis. These data are summarized in Table 6 .
Two other RCTs evaluated patients undergoing liver transplantation. One included 2 treatment arms (different intravenous regimens) and a control group receiving no nutritional support. 25 The other compared parenteral to enteral nutrition. 147 Several trials compared parenteral nutrition that was enriched with branched-chain amino acids to a variety of other interventions in patients with hepatic encephalopathy. 148 -155 Mortality. Neither parenteral nutrition nor protein-sparing therapy improved survival.
Morbidity. With regard to alcoholic hepatitis, the only data regarding total complications came from 2 of the protein-sparing therapy trials 126, 129 ; no effect was demonstrated. There were nonsignificant trends in both a This represents the difference between the outcome in the treated group and the control group; a negative number represents a benefit for the treated group. b Although 1 bone marrow transplantation trial reported an improved survival, 94 this was not demonstrated when all 4 trials 91-95 were combined; absolute risk difference equaled Ϫ5% (Ϫ14%, ϩ5%). Only 3 of these trials provided parenteral nutrition during the time when the transplantation was performed [92] [93] [94] [95] ; when only these 3 trials were combined, absolute risk difference equaled Ϫ9% (Ϫ22%, ϩ4%). c A negative absolute risk difference indicates that the response rate in the control group was higher than in the recipients of the parenteral nutrition. d 13 of these 15 RCTs were chemotherapy trials.
trials for parenteral nutrition to be associated with less encephalopathy. 96, 97 In most of these RCTs of alcoholic hepatitis, hyperbilirubinemia improved more rapidly in those who received either form of intravenous nutrition. Parenteral nutrition had no demonstrable impact on the course of patients receiving liver transplants. In 1 of the trials, 25 the control patients were in the intensive care unit for a longer time (6 days) than were the patients in the other 2 groups (3-4 days). No data regarding graft rejection were provided.
Hepatic encephalopathy improved more often and/or more rapidly in the recipients of the branched-chain amino acid-enriched solutions.
No data were available regarding what effect, if any, parenteral nutrition or protein sparing has on gastrointestinal bleeding in patients with liver disease.
Summary and implications of the data. Only a limited number of trials are available. There is no apparent effect of parenteral nutrition or protein-sparing therapy on mortality. Parenteral nutrition may result in a more rapid decline in hyperbilirubinemia, but the clinical relevance of such an improvement is undefined.
The role of parenteral nutrition after liver transplantation is unknown. The trials were so small that marked differences between groups would be needed to achieve statistical significance.
A previously published meta-analysis concluded that intravenous branched-chain amino acid-enriched solutions (alone or as part of a parenteral nutrition regimen) are of benefit in treating hepatic encephalopathy. 156 However, the expense of the nutritional intervention is higher than that of other available nonnutritional ones. 131 
Acute Pancreatitis
Trials. Two RCTs evaluated the role of parenteral nutrition in patients with acute pancreatitis. One of them 98 included a second treatment arm (protein-sparing therapy). Two other small trials compared parenteral to enteral nutrition. 157, 158 All of these trials excluded patients with severe disease. These data are summarized in Table 7 .
Mortality. No differences in mortality were observed between the patients who received parenteral nutrition and the controls.
Morbidity. Compared with standard therapy, parenteral nutrition resulted in more complications and a longer hospitalization in 1 trial. 99 Compared with enteral nutrition, parenteral nutrition was associated with a higher complication rate in 1 trial. 158 Parenteral nutrition was not shown to have any effect on the development of pseudocysts, abscesses, phlegmons, or pain resolution.
Duration of hospitalization and costs. The patients receiving parenteral nutrition had significantly longer hospitalizations and higher costs in 1 RCT. 99 Summary and implications of the data. Only a few RCTs have evaluated the clinical efficacy of parenteral nutrition in patients with acute pancreatitis. Two studies compared parenteral nutrition to standard therapy. One found no statistically significant effect from parenteral nutrition or protein-sparing therapy, and the other found that the use of parenteral nutrition prolonged the length of hospitalization, increased cost, and, possibly caused more complications.
Two small RCTs compared enteral with parenteral nutrition. One found no difference, and the other noted an increased rate of complications in the recipients of parenteral nutrition.
It is difficult to draw firm conclusions when the only data available are from a few small trials. However, the data suggest that parenteral nutrition not only is not beneficial, but also causes net harm in patients with mild pancreatitis. We are not aware of any RCTs that evaluated the efficacy of parenteral nutrition in patients with more severe disease. 
Inflammatory Bowel Disease
Trials. Two RCTs compared parenteral nutrition to no nutritional therapy in patients with acute ulcerative or Crohn's colitis. 100, 101 Several RCTs compared parenteral to enteral nutrition in patients with acute ulcerative colitis 159 or during exacerbations of Crohn's disease. 160 -162 The data are summarized in Table 8 .
Mortality. There was no impact of parenteral nutrition on mortality when compared with no nutritional support. 100, 101 No data were available from the other trials.
Morbidity. No effect on disease remission or subsequent need for surgery was observed when parenteral nutrition was compared with no nutritional support or to enteral nutrition. None of these trials addressed the duration of diarrhea.
Summary and implications of the data. Parenteral nutrition provided no benefit in the treatment of Crohn's or ulcerative colitis, and it may be equivalent to enteral nutrition with regard to treating patients with active Crohn's disease of the small intestine. Parenteral nutrition could thus be inferred to be inferior to standard therapy, as 3 separate meta-analyses have concluded that clinical remission is achieved more frequently with corticosteroids than with enteral nutrition. [163] [164] [165] One additional trial evaluated the role of bowel rest; both treatment groups received parenteral nutrition and steroids, but 1 of the groups also was allowed to eat. 166 No differences were observed. All of these data indicate that bowel rest is not necessary to achieve remission in Crohn's disease.
Pediatrics
Trials. The RCTs of parenteral nutrition that were identified in the pediatric literature included conditions that have already been discussed-perioperative patients 32 and patients receiving oncologic therapy. 60, [85] [86] [87] [88] Five RCTs evaluating the effect of parenteral nutrition on low-birth-weight infants [102] [103] [104] [105] [106] were subjected to meta-analysis; the estimated absolute risk differences for mortality and morbidity are presented in Table 9 . One other RCT assessed protein-sparing therapy in low-birthweight infants, 130 and 1 trial compared different levels of caloric delivery. 167 Mortality. Parenteral nutrition did not have a significant impact on survival. In the trial of protein-sparing therapy, which included only 30 patients, the mortality rates tended to be higher in the treatment group (47%) than in the control group (27%), but the difference was not statistically significant.
Complications. Parenteral nutrition did not affect either the total or infectious complication rates. No effect of parenteral nutrition was observed with regard to the development of enterocolitis 104, 106 or respiratory problems. 104 Infectious complications developed in 40% of the patients receiving protein-sparing therapy and 27% of the controls. Although the survivors in the proteinsparing therapy group had significantly fewer apneic episodes than did the controls who lived, most of those who died required intubation and respiratory support, and there were more deaths in the treated group.
Duration of hospitalization. Additional nutrients should promote more rapid weight gain, and a subsequent earlier discharge, in neonates who are hospitalized only because of low birth weight. However, more rapid weight gain did not translate into an earlier discharge. 103, 167 Summary and implications of the data. No benefits from parenteral nutrition were observed. Although this nutritional intervention may increase the rate of weight gain, there is no evidence that that translated into any meaningful clinical outcome, including an earlier hospital discharge. It is generally believed that such neonates require early nutritional support because of (1) a lack of intrinsic energy stores and (2) nutrient requirements for growth and development. For many of these infants, enteral nutrition may suffice. We have no direct data assessing how long such babies can endure starvation.
Acquired Immunodeficiency Syndrome
Trials. One trial randomized 31 malnourished patients with acquired immunodeficiency syndrome (AIDS) into a group receiving home parenteral nutrition for 2 months or into a group receiving nutritional counseling. 107, 108 Mortality. No difference in survival was reported in the initial report; 3 patients in each group died. 107 Subsequently, the investigators reported that survival was improved in the recipients of parenteral nutrition, 108 but these data were not analyzed in accordance with the initial treatment assignment.
Morbidity. The recipients of the parenteral nutrition had improved anthropometric measurements and weight gain, and they subjectively felt better. No difference in the incidence of AIDS-related complications was observed.
Summary and implications of the data. This single RCT did not show that parenteral nutrition altered the progression of AIDS. It did improve body weight and subjective feelings of well-being, but the study was not blinded.
Pulmonary Disease
Trials. Two trials assessed the role of parenteral nutrition in pulmonary disease. One assessed the role of home parenteral nutrition in patients with cystic fibrosis. 109 The other assessed malnourished hospitalized patients with chronic obstructive pulmonary disease. 110 The results from these 2 RCTs are summarized in Table 10 .
Mortality. No significant differences were observed, although the mortality rates in the control groups of both trials were higher than those in the recipients of parenteral nutrition.
Morbidity. The rates of catheter infections were not significantly different. 109 a This represents the difference between the outcome in the treated group and the control group; a negative number represents a benefit for the treated group. b Two RCTs provided the rates of enterocolitis in the treated/control groups; these were 5%/5% 104 and 5%/0% 106 respectively. c One report indicated that respiratory problems developed in 10% of the treated group and 0% of the controls.
Duration of hospitalization. In the trial of patients with cystic fibrosis, the average number of days spent in the hospital over a 4-month period was not significantly different between the 2 groups. 109 Summary and implications of the data. There are only limited data available; no benefit of parenteral nutrition was established.
Renal Failure
Trials. No RCTs were identified that compared parenteral nutrition to no nutritional support in patients with either acute or chronic renal failure. Several trials assessed non-enteral nutrient delivery in patients with chronic renal failure. The techniques used included intradialytic parenteral nutrition (the provision of amino acids and calories during hemodialysis), 168 -170 peritoneal dialysis solutions containing dextrose and amino acid solutions, 171 and intravenous amino acids after each dialysis run. 172 None of these trials reported clinical outcomes.
Five RCTs evaluated the use of essential amino acidbased parenteral nutrition during acute renal failure. Three used control groups that received isocaloric amounts of dextrose without any amino acids, [173] [174] [175] and the other 2 compared this type of parenteral nutrition to parenteral nutrition containing a standard amino acid formulation. 176, 177 Mortality/morbidity. A systematic review of intradialytic parenteral nutrition concluded that the evidence supporting this therapy was weak, and a clear recommendation could not be made. 178 A meta-analysis of the 5 RCTs conducted in patients with acute renal failure concluded that, while recovery from an acute episode of organ dysfunction was improved by essential amino acid-based parenteral nutrition, overall survival was unchanged. 179 Summary and implications of the data. Compared with high-calorie intravenous dextrose infusions or parenteral nutrition containing standard amino acids, essential amino acid-based parenteral nutrition may improve the rate of recovery of renal function in patients with acute renal failure; there is no evidence that this type of parenteral nutrition improves survival. No RCTs have evaluated the effect of parenteral nutrition on the clinical outcomes of patients with chronic renal failure.
Burn Injury
Trials. No RCTs were identified that compared parenteral nutrition to no nutritional support in patients with burns. Three studies randomized patients to groups receiving or not receiving parenteral nutrition, but each of the control groups received enteral nutrition 180, 181 or intravenous lipid and hypertonic dextrose solutions. 182 Mortality. In all 3 trials, the mortality rates in the groups receiving the parenteral nutrition were higher; in 1 of these, that difference was statistically significant. 180 Summary and implications of the data. There were no trials comparing parenteral nutrition to no nutritional therapy. When parenteral was compared with enteral nutrition, the former was associated with higher mortality rates.
Other Critical Illness
Trials. One RCT, available only in abstract form, randomized patients with traumatic injuries to immediate parenteral nutrition or to no nutritional support. 111 Seven RCTs have compared parenteral with enteral nutrition in patients who suffered severe blunt abdominal trauma. 111, [183] [184] [185] [186] [187] [188] Three of the reports included in the parenteral nutrition meta-analysis (1 containing 2 treatment arms) provided data regarding the length of time that mechanical ventilation was required. 22, 35, 104 These data are summarized in Table 11 . Mortality. Immediate parenteral nutrition did not affect mortality in patients with trauma. 111 Morbidity. The trial of immediate parenteral nutrition found no difference in the subsequent infectious complication rates (10/20, 50% [treated] vs. 10/23, 43%
[controls]). 111 Some, 111,183-185 but not all, 186 -188 of the RCTs that compared the 2 forms of nutritional support found higher rates of infectious complications in those receiving parenteral nutrition.
Parenteral nutrition did not affect the length of time mechanical ventilation was required.
Summary and implications of the data. There is only a limited amount of information available. Parenteral nutrition, compared to enteral nutrition, may or may not result in more infections in patients with abdominal trauma. Parenteral nutrition did not shorten the time that patients required mechanical ventilation.
Home Parenteral Nutrition
Data. Patients who require parenteral nutrition for protracted times (months, years, or even a lifetime) can be treated at home. The topic of home parenteral nutrition was recently subjected to a systematic review for use by the health care system in the United Kingdom. 189 This section will summarize the findings of that effort, with some additional comments from a few reports that subsequently have become available. The authors of the systematic review did state that their conclusions were based on data that were, in general, of poor scientific quality.
The prevalence of home parenteral nutrition in adult Europeans is about 1-12/1,000,000 residents, 189, 190 a rate that differs by at least 10-fold from estimates made in the United States (120/1,000,000). 9 At least some of this gap is related to methodological differences in the data collection. The European estimate is based on "point-prevalence" studies (assessing the number of patients enrolled in home programs on a particular day), whereas the U.S. estimate results from counting all of the patients observed over an entire year. 191 Because many patients are in the system for less than 1 year, the former method will underestimate the numbers. However, it is unlikely that this explanation alone accounts for a 10-fold difference, and home parenteral nutrition is probably more frequently utilized in the United States.
The use of home parenteral nutrition has been increasing on both sides of the Atlantic. It has been suggested that the additional utilization in the United States is caused by its provision there to patients with cancer. 9 Although some of these patients die within weeks of starting the therapy, most of them live for months (with or without ongoing cancer treatment). To qualify for Medicare reimbursement for home parenteral nutrition, patients (including those with cancer) must require parenteral nutrition and be expected to live for at least 3 months.
There is a dramatic difference in survival between patients with benign disease, particularly those with Crohn's disease, and those with malignancy. 189 The 1-year survival rates of patients receiving home parenteral nutrition for Crohn's disease are usually in excess of 90%. Patients with cancer have 1-year survival rates of 15%-30%.
There is limited information about quality of life and functional assessment of patients receiving home parenteral nutrition. 189 In general, these parameters are better in younger individuals with benign disease who have been on the therapy for longer periods of time. One uncontrolled trial suggested that quality of life in patients with Crohn's disease improved after this nutritional support was begun. 192 However, patients who are receiving home parenteral nutrition do not perceive their lives as being normal; their quality of life is comparable to that of hemodialysis patients. 193 The use of home parenteral nutrition is associated with serious medical complications. Complications related to the intravenous catheter itself, namely sepsis, occlusion, and central vein thrombosis, were estimated to occur 0.34, 0.071, and 0.027 times per catheter-year 189 and are likely related to factors such as the underlying illness and the diligence with which catheter care is performed. 8, 189 A number of other problems, such as liver disease, metabolic bone disease, and psychiatric problems (especially depression), also occur, but their true incidences are difficult to establish.
Data regarding the impact of home parenteral nutrition on resource utilization are limited. A recent costutility analysis suggested that 1 year of quality life would be £69,000. 189 The cost of such home care in the United Kingdom was estimated to be £45,000 for the first year and £36,000 for each year thereafter. 190 In 1992, the daily Medicare allowable charge for home parenteral nutrition was $200 -$400 (equivalent to $73,000 -$146,000 per year). 9 Four of the previously discussed RCTs used parenteral nutrition delivered at home. 62, 91, 107, 109 They all assessed the utility of longer-term parenteral nutrition in disease states other than irreversible gastrointestinal tract failure (cancer chemotherapy, bone marrow transplantation, AIDS, and cystic fibrosis). The data are summarized in Table 12 . No benefit was observed with regard to mortality or infectious complications.
Summary and implications of the data. Patients presumed to have irreversible gastrointestinal tract failure (e.g., short bowel) will succumb to starvation unless parenteral nutrients are provided. (The use of parenteral nutrition in this scenario is analagous to providing hemodialysis to patients with end-stage renal disease.) The decision to use home parenteral nutrition in other patient populations should weigh the risk of complications (probably at least 2% per year in the best of hands) and economic costs (probably about $100,000 annually) against the expected benefit.
Based on the data, the increased use of home parenteral nutrition in patients with cancer may not be justified. One trial of home parenteral nutrition in patients with testicular cancer did not show any benefit from such therapy. 62 Although the trial was conducted for only 10 weeks, there is no compelling reason to believe that longer-term usage would have improved the outcome. When parenteral nutrition has been used in hospitalized patients with cancer, it has caused more complications and has impaired the response to chemotherapy. We have no data to determine if the benefits of home parenteral nutrition outweigh its risks and costs in cancer patients who have compromised gastrointestinal function and life expectancies measured in months. However, those who develop prolonged (or even irreversible) gastrointestinal tract failure while receiving effective (especially curative) cancer treatment are candidates for long-term home parenteral nutrition.
Potential Limitations of Data From RCTs and Meta-Analysis
The data from the RCTs have been disappointing with respect to proving that parenteral nutrition improves clinical outcome. It is generally accepted that protein-energy malnutrition is accompanied by adverse clinical consequences. It would seem to be intuitively obvious that the correction of that state of malnutrition should improve outcome. However, there are several possible reasons why the RCTs have not shown such an effect.
It may simply be that parenteral nutrition is not effective. This would be the case if malnutrition did not cause the poor outcome. Even if malnutrition were partly responsible for the poor outcome, the side effects of the parenteral nutrition might equal the benefits it provided, therefore no net effect would result. It is possible that we are simply ignorant with regard to which nutrients are necessary and which are not (or even harmful), and we may be using the wrong nutritional formulations.
Many of these RCTs were conducted at a time when the standard was to provide large amounts of calories. The resultant metabolic abnormalities, especially hyperglycemia, may have been responsible for infections and other complications. This practice is now known as "overfeeding," and current practices use lower levels of caloric intake. Unfortunately, at this time we have no established standard as to what level of caloric intake constitutes overfeeding.
It may also be that the RCTs may not have included, or at least may not have been able to identify, the subgroup of patients who will benefit. As we observed in the introduction, it is certainly possible that the benefit of parenteral nutrition will be confined to those with severe malnutrition, as was suggested by the post priori subgroup analysis in the VA cooperative study. 48 We should also consider some of the limitations that arise when we attempt to make clinical decisions from data from RCTs or meta-analyses. Could any of these have been a factor in this review?
Identification of Trials
The systematic search may have failed to identify all of the trials. This clearly is a problem when the search strategy relies solely on computer searches; over half of the pertinent reports can be missed. 194 There is no gold standard to which any given strategy can be compared. The search we used began over 2 decades ago and did not only rely on computer searching. One validation of it is that we identified more trials than are included in other published reviews. Nonetheless, we cannot be certain that we found all of the RCTs.
Randomized Controlled Trials
This technical review emphasized data from RCTs. However, randomized trials do have potential pitfalls. These pitfalls include type I and II errors, randomization allocation, blinding, selection and definition of endpoints, and intent-to-treat analysis.
Type I errors occur when differences that are not true are perceived to be so because the P value is Ͻ 0.05. Publication bias can produce a type I error because studies that show significant differences are more likely to be submitted. 195 If this systematic review were to have missed existing data because they were unpublished, the true effect of parenteral nutrition would probably be even less favorable than what was reported.
Type II errors occur when true differences are not demonstrated because the sample size studied is inadequate to make that difference statistically apparent. One of the advantages of meta-analysis is that it does combine data from multiple trials, thereby increasing the power to identify smaller differences. Nevertheless, especially in the clinical conditions with only limited amounts of data, we cannot exclude the possibility that favorable trends actually represent true differences. Examples in which this might be an issue include the effect of parenteral nutrition on patient mortality in certain diseases (bone marrow transplantation or chronic pulmonary disease) and its effect on jaundice and encephalopathy in patients with alcoholic hepatitis.
When patients are assigned by a quasirandomization technique (e.g., group assignment based on day of the week or record number), exaggerated treatment responses tend to be observed. 196 In fact, any allocation scheme that is not explicitly concealed tends to show larger treatment effects. 196 Many trials did not publish the precise means whereby the randomization was accomplished. We attempted to avoid this problem by excluding quasirandomized trials. However, we cannot be sure that some of the included trials did not have defects in randomization allocation because the precise method of allocation usually was not reported. Again, any error so introduced would tend to overestimate the benefit of parenteral nutrition.
It is very difficult to blind the intervention of parenteral nutrition. The subsequent assessment of subjective outcomes can be influenced by knowledge of which treatment was administered. In general, such a bias also acts to increase the observed effect of the intervention. 196, 197 These and other methodologic practices (a priori power calculations, clear definitions of endpoints, and intent-to-treat analyses) can make an impact on the size of the observed treatment effect. Scoring systems ("quality assessment") have been developed to measure the likelihood that bias was present in the performance of the trial. 197 We initially attempted to grade a few RCTs according to 1 such system, 198 and we subsequently attempted to undertake a more subjective assessment of the trial methodology. Both attempts were unsuccessful; the scores of most of the trials were relatively low and very similar. This problem arose for several reasons:
1. Many of the trials were published in an era when providing many of these details was not encouraged, tending to make the scores similar and low. 2. Some of the trials, designed to evaluate intermediate endpoints, reported clinical outcomes. Although the sample size was adequate to address the nonclinical question, it was inadequate to answer the clinical question. Thus, the trial score was downgraded. 3. The inability to blind the intervention produced lower and less divergent scores. 4. The elimination of quasirandomized trials congregated the scores, although it also raised them.
As we were unable to make formal quality assessments of the individual RCTs, we did not perform a subgroup analysis based on trial quality. However, because lowquality trials tend to show larger treatment effects, 132, 197 the true effects of parenteral nutrition may be less beneficial than our estimated effects suggest.
Meta-analysis
Meta-analysis allows trials to be combined, thereby providing more precision and power. However, the process does have limitations. It is retrospective and relies on the available information. Inadequate study design, incomplete or nonuniform reporting of data, and publication bias can result in inaccurate or missing data. Heterogeneity, as we noted previously, can make the combination of studies problematic. At times, the conclusions of large RCTs have been at variance with the conclusions of meta-analyses of smaller trials. 199 Metaanalysis should be viewed as an imperfect technique that can, nevertheless, provide insight.
Heterogeneity refers to the disparity of studies. If the studies were too dissimilar, it would make little sense to try to combine the results. Meta-analysis deals with heterogeneity in several ways. One may simply choose not to combine the data. Alternatively, one can use a more demanding statistical test of significance (random effects model) or perform subgroup analyses. Subgroup analyses examine particular factors that may influence the outcome and be responsible for the heterogeneity. Each factor is identified (ideally, a priori), and the statistical combination is performed in the subset of trials that contains it.
We assumed that heterogeneity would be present and based all of the calculations on the random effects model. Indeed, statistical tests designed to detect heterogeneity usually indicated that it was present. To look for more subtle effects of parenteral nutrition, we accepted the problem of heterogeneity and chose to combine all of the trials in global analyses.
The protein-sparing therapy meta-analysis was validated. The single large surgical trial did agree with the estimates that were obtained by combining all of the other perioperative RCTs.
Future Research Directions
No data are available to address the issue of how long patients who are underweight, normal weight, or overweight can tolerate limited nutrient intake. This is particularly the case for those individuals who have impaired gastrointestinal function. Likewise, we have no data-based insight into the need for parenteral nutrition in individuals with markedly restricted nutritional reserves (e.g., the severely malnourished adult or the young child) or those with coexistent highly catabolic disease processes (especially the subgroup who are not candidates for enteral nutrition). Because parenteral nutrition is an expensive and potentially dangerous intervention, a more precise definition of these time periods is needed.
The uses of parenteral nutrition in the perioperative patient and in the cancer patient undergoing radiation or chemotherapy have been extensively evaluated. In general, the results have been disappointing, but 3 areas do require further elucidation. One is a more precise definition of the effect of parenteral nutrition in patients with cancer of the esophagus or stomach who are facing surgery. Although parenteral nutrition may have some efficacy, it is not clear whether the intervention can be justified from the perspective of resource utilization. The second is with regard to hospitalized patients who are about to undergo bone marrow transplantation. At this time, we do not know whether or not survival is improved. The third is the utilization of home parenteral nutrition in cancer patients with expected survivals of more than 3 months who have major compromises of gastrointestinal function.
Clinical Use of Parenteral Nutrition

Indications
Although the available data do not justify the routine use of parenteral nutrition in most hospitalized patients, selected patients will require this intervention. The indication for initiating parenteral nutrition is to prevent the adverse effects of protein-energy malnutrition in patients unable to consume adequate protein and energy for a prolonged period of time via the gastrointestinal tract. However, the precise definitions of "adequate" and "prolonged" are not clear. The number of days or weeks of starvation or semistarvation that can be tolerated by any given patient depends on the amount and type of inadequate nutrient intake, the amount of endogenous fat (fuel) and muscle mass, and the rate of fat and muscle catabolism. In lean persons, death from starvation has been associated with weight loss of Ͼ35%, protein depletion Ͼ30%, fat depletion Ͼ70% of fat stores, and body size (body mass index of 13 kg/m 2 for men and 11 kg/m 2 for women). 200, 201 In lean men, death occurs after approximately 2 months of starvation when more than 35% (about 25 kg) of body weight is lost. 201 In contrast, extremely obese persons can fast for more than a year without adverse consequences. 202 Although it is not clear how long an ill adult patient can tolerate partial or total starvation without adverse effects, there is no evidence that withholding parenteral nutrition for at least 7 days is harmful in patients who are not severely malnourished (defined as Ͼ20% unintentional weight loss, 1 subjective global assessment, 4 or the nutrition risk index 48 ). For most adult hospitalized patients, a conservative approach would be to restrict parenteral nutrition to those who will not be able to receive oral or enteral feeding for at least 10 -14 days. No data are available to determine the length of time that starvation or semistarvation can be tolerated in growing children or adults with severe malnutrition. Parenteral nutrition should not be given to the terminally ill patient.
Nutrient Requirements and Formulations
Parenteral solutions supply basic nutrients, including fluid, protein, carbohydrate, fat, minerals, trace elements, and vitamins. Ideally, the nutritional formulation should be tailored to each patient's needs. However, standard formulations usually can be used to meet the nutrient needs of most patients.
Energy. Requirements can be estimated by using equations that calculate resting energy needs (Table  13) . 203 These equations are much more accurate in normal-weight healthy individuals than in hospitalized patients because of the variability in energy expenditure associated with illness or injury. Malnutrition and negative energy balance decrease resting energy expenditure, whereas metabolic stress (e.g., inflammatory diseases or trauma) often increases energy requirements. It is rare for illnesses or injury to increase resting energy expenditure by more than 50% of pre-illness values. 204 These predictive equations can be helpful in estimating initial energy needs, with the understanding that continued modification may be needed, depending on the patient's clinical course. It is better to err on the side of giving too few than too many calories to patients, because it is likely that infectious and metabolic complications are increased by overfeeding.
Protein. Amino acid requirements can vary based on the amount of nonprotein calories provided (protein requirements increase with suboptimal energy intake), overall energy requirements (protein requirements usually increase with increased energy requirements), and protein quality (inadequate amounts of any of the essential amino acids decreases efficiency of protein utilization). Amino acids delivered to patients should be included in the estimate of energy provided by the parenteral formulation because these amino acids can be oxidized or replenish endogenous amino acids that have been oxidized. General guidelines for protein requirements in hospitalized patients are provided in Table 14 . 203 Crystalline amino acid solutions used in parenteral nutrition formulas are of high biological quality; essential amino acids make up a large percentage (usually 40%-50%) of the total amino acids. Some amino acid solutions have been modified for specific disease states, such as those enriched in branched-chain amino acids or those containing mostly essential amino acids. The clinical efficacy of these formulations has been reviewed previously.
Carbohydrate. There is no dietary requirement for carbohydrate because glucose can be synthesized from endogenous precursors. However, providing approximately 150 g of carbohydrate per day for tissues that require glucose (i.e., bone marrow, erythrocytes, leukocytes, renal medulla, eye tissues, and peripheral nerves) or prefer it (i.e., brain) can spare the use of amino acids for gluconeogenesis. The protein-sparing effect of carbohydrate and fat are similar once glucose requirements for these tissues are met. 205 The amount of infused glucose oxidized is directly proportional to the amount of glucose administered until a threshold level is reached. Providing excessive amounts of glucose does not increase glucose oxidation but could have adverse consequences by causing hyperglycemia, fatty liver, and excessive carbon dioxide production. 206 In fact, excessive glucose calories can result in additional carbon dioxide in patients with pulmonary insufficiency. 207 Lipid. Lipid emulsions are isosmolar and contain triglycerides from soybean oil or a combination of soybean and safflower oil. The fatty acid content is comprised mostly of essential fatty acids, such as linoleic and linolenic acid. The emulsified particles are approximately the same size and structure as chylomicrons. They consist of a hydrophobic triglyceride core surrounded by polar phospholipids. Commercially made lipid emulsions are distinct from chylomicrons in that the emulsions contain mostly essential fatty acids and are devoid of cholesterol or protein. Lipid emulsion particles rapidly acquire apolipoproteins from contact with circulating high-density lipoprotein particles in the bloodstream and are metabolized as nascent chylomicrons. The optimal percentage of calories that should be infused as fat is not known, but 20%-30% of total calories is reasonable for most patients. A minimum of approximately 5% of total calories as a lipid emulsion is necessary to prevent essential fatty acid deficiency in patients receiving continuous parenteral nutrition. The infusion of lipids should not exceed 1.0 kcal/kg per hour (0.11 g/kg per hour) because most complications associated with intravenous lipid emulsions occur when this infusion rate is exceeded. 208 Lipid emulsions should not be administered to patients who have serum triglyceride concentrations Ͼ400 mg/dL and may not be necessary at all in obese patients. Underfeeding obese patients by the amount of lipid calories that would normally be given (e.g., 20%-30% of calories) facilitates mobilization of endogenous fat stores for fuel and may improve insulin sensitivity and glucose control.
Major minerals and micronutrients. The daily recommended parenteral intake for major minerals and micronutrients (trace minerals and vitamins) is listed in Table 15 . 209 Large mineral losses in patients with protracted vomiting, large volume fistulas, high ostomy output, or severe diarrhea will require additional supplementation.
Venous Access
Parenteral administration of hypertonic parenteral nutrition solutions requires infusion through a high-flow central vein, such as the superior vena cava. The traditional approach to central venous access is via an infraclavicular subclavian vein, advancing the catheter tip to the junction of the superior vena cava and right atrium. This approach has the advantages of easy dressing maintenance, better patient comfort and mobility, and probably a lower risk of infection than internal jugular, saphenous, or femoral vein insertions. Peripherally inserted central venous catheters (peripherally inserted central catheter [PICC] lines), which eliminate the risk of pneumothorax, also can be used to provide central parenteral nutrition, but only in patients with adequate antecubital venous access.
Initiating and Monitoring Parenteral Nutritional Support
A detailed medical examination, including history, physical examination, and laboratory studies, is needed to evaluate for specific nutrient deficiencies and to determine nutritional needs before initiating intravenous feeding. Dextrose from concomitant intravenous infusions should be evaluated as part of total energy requirements, and the volume of other intravenous fluids adjusted to accommodate for the volume of parenteral nutrition being administered. Careful monitoring is needed to ensure safety and adequacy of therapy. Vital signs should be checked every 8 hours. Body weight, fluid intake, or fluid output should be measured daily in selected patients.
Serum electrolytes, phosphate, and glucose should be measured daily until stable and then rechecked less frequently. Serum glucose may need to be checked every 4 -6 hours if hyperglycemia is a concern. If lipid emul- sions are being administered, serum triglycerides should be checked to ensure adequate clearance in patients at risk for hypertriglyceridemia. Careful attention to catheter insertion and the catheter site is mandatory to decrease catheter-related infections. Gauze dressings should be changed every 48 -72 hours or when contaminated or wet; transparent dressings can be changed weekly. Parenteral nutrition tubing should be changed every 24 hours. An in-line 0.22-m filter should be used with lipid-free central parenteral nutrition, and a 1.2-m filter should be used when a total nutrient admixture containing a lipid emulsion is infused and when quality control to prevent particulate matter contamination cannot be ensured; filters should be replaced every 24 hours with tubing changes. Adjusting the parenteral formulation may be necessary if the patient's clinical condition or treatment changes.
Complications
Parenteral nutrition can cause serious complications related to mechanical aspects of line insertion, infections from contaminated solutions or inadequate catheter care, and metabolic abnormalities from inappropriate nutrient formulations. In addition, serious hepatobiliary and bone complications are associated with long-term parenteral nutrition. The risk of most complications that occur in the hospital is decreased when the administration of parenteral nutrition is supervised by an experienced nutrition support team. 210 Central line insertion can cause damage to local structures and organs (pneumothorax, brachial plexus injury, subclavian and carotid artery puncture, hemothorax, thoracic duct injury, and chylothorax) and other adverse events (advancing the catheter upward into the internal jugular vein and air embolism) during attempted venous cannulation.
Inappropriate nutrient administration can cause nutrient excesses or deficiencies, such as fluid overload, hypertriglyceridemia, hypercalcemia, hypoglycemia, hyperglycemia, and specific nutrient deficiencies. Hyperglycemia is a common problem that can increase the risk of infection, particularly when the blood glucose exceeds 200 mg/dL. If the patient's initial blood glucose is Ͼ200 mg/dL, better glycemic control should be obtained before initiating parenteral nutrition. Rigorous efforts should be made to keep blood glucose between 100 mg/dL and 200 mg/dL when initiating parenteral nutrition and between 100 mg/dL and 150 mg/dL after the parenteral nutrition infusion has been stabilized. Blood glucose should be kept below 120 mg/dL in pregnant patients to avoid complications of gestational diabetes and large-for-gestational-age births. Aggressive serum glucose monitoring with appropriate insulin administration is frequently necessary to achieve and maintain desired glucose homeostasis.
Subclavian vein thrombosis can be detected by a careful radiological examination in up to 50% of patients who receive central parenteral nutrition. 211 However, clinically significant thromboses are rare. Several cases of fatal microvascular pulmonary emboli in patients receiving total nutrient admixtures have been reported. 212 This complication was caused by calcium and phosphorous precipitates that were not visible in admixture and underscores the importance of maintaining strict physicalchemical compatibility standards. Visual inspection of parenteral nutrient solutions does not guarantee elimination of the risk of infusing dangerous microprecipitates because the size limit for visual detection of microprecipitates (50 -100 m) is much larger than the diameter of the smallest pulmonary capillaries (5 m). 213 Infectious complications from microbial and fungal contamination of solutions are rare in hospitals that use rigorous protocols for parenteral nutrition solution preparation. Central catheter-related sepsis is usually caused by entry of organisms at the catheter exit site or contamination at tubing connections. The presence of a fever in a patient who is receiving parenteral nutrition may or may not be related to the central venous catheter. Therefore, an appropriate history, physical examination, and laboratory and blood tests should be performed to identify the source of infection accurately. If there is no obvious etiology for infection and catheter-related sepsis is suspected, the following steps should be considered: (1) evaluate the catheter insertion site and culture any drainage, (2) obtain blood cultures from a peripheral vein and the central vein catheter, and (3) begin empiric antibiotic therapy. Immediate catheter removal is mandatory (as with any central venous catheter) if there is a purulent discharge or abscess at the insertion site or if the patient is in septic shock without an apparent etiology. Catheter removal should also be considered when there is: (1) persistent or recurrent catheter-related bacteremia, (2) Candida species, Staphylococcus aureus, or Pseudomonas infection, (3) polymicrobial infection, or (4) persistent fever for 72-96 hours after initiating appropriate antibiotics, and there is no other obvious source of infection. Whenever the catheter is removed, the tip should be cultured.
Several hepatic abnormalities have been observed in adults receiving central parenteral nutrition. 214 Although these abnormalities are usually benign and transient, a small subset of patients develops more serious and progressive disease. Most of the former complica-tions occur within 4 weeks of starting parenteral nutrition, whereas the more serious complications occur later, usually after 16 weeks of therapy. Hepatic complications associated with long-term parenteral nutrition occur more frequently and are more severe in infants than in adults.
The hepatic abnormalities include biochemical (elevated serum aminotransferases and alkaline phosphatase) and histological (steatosis, steatohepatitis, lipidosis and phospholipidosis, cholestasis, fibrosis, and cirrhosis) alterations. Interventions that have been used (albeit largely unproven) to prevent or treat hepatic complications include providing a portion (20%-40%) of calories as fat, cycling the infusion (stopping for at least 8 -10 hours/day), avoiding excessive calories, and treating with metronidazole or ursodeoxycholic acid. In addition, other possible causes of liver disease should be considered. When cholestasis is present, copper and manganese supplementation should be eliminated or decreased to prevent dangerous accumulation in the liver and basal ganglia.
The biliary complications associated with central parenteral nutrition are acalculous cholecystitis, gallbladder sludge, and cholelithiasis. These usually occur in patients who have received the parenteral nutrition for more than 3 weeks. Acalculous cholecystitis is particularly associated with major trauma, severe systemic illness, and major operative procedures. The absence of enteral feeding leads to gallbladder stasis and consequent sludge and stones. 215 Stimulating gallbladder contraction and emptying by either enteral feedings or cholecystokinin injections reduces, or even completely prevents, sludge and gallstone formation. 216, 217 Metabolic bone disease, including osteomalacia and osteopenia, has been observed in patients receiving central parenteral nutrition for more than 3 months. 218 The clinical manifestations of bone disease range from asymptomatic, radiologic evidence of demineralization to severe bone pain and fracture. The cause of metabolic bone disease is not known; mechanisms that have been proposed include aluminum toxicity, vitamin D toxicity, and negative calcium balance.
Refeeding the Severely Malnourished Patient
Aggressively refeeding patients who are severely malnourished can have adverse clinical consequences ("refeeding syndrome"), especially in the first few days. 219, 220 These potentially life-threatening complications include: (1) fluid overload and congestive heart failure (due to excessive fluid and sodium administration in conjunction with decreased cardiac mass and contractility); (2) serum electrolyte abnormalities (particularly hypophosphatemia and hypokalemia caused by insulinstimulated tissue uptake from plasma); (3) cardiac arrhythmias (including ventricular tachyarrhythmias); and (4) glucose intolerance with hyperglycemia.
The complications associated with refeeding the severely malnourished patient make it important to perform a careful medical evaluation and correct electrolyte abnormalities before initiating parenteral feeding. The following general guidelines are recommended for the first few days of parenteral nutrition in severely malnourished patients: (1) limit fluid intake to approximately 800 mL/d plus insensible losses (adjust as needed in patients who have evidence of fluid overload or dehydration; changes in body weight Ͼ 0.25 kg/d, or 1.5 kg/wk, probably represent fluid accumulation rather than tissue repletion); (2) limit daily calorie intake to approximately 15 kcal/kg, containing about 100 g of carbohydrate and about 1.5 g protein/kg per day; (3) restrict sodium to approximately 60 mEq or 1.5 g per day; (4) provide liberal amounts of phosphorus, potassium, and magnesium as long as the patient has normal renal function; and (5) monitor body weight, fluid intake, urine output, and plasma glucose and electrolyte values daily during the first several days of refeeding. 
Conclusions
Recommendations
The systematic review process allows clinicians to use evidence when they formulate decisions about patient care. Certainly, a proposed therapeutic intervention should be used when it has established efficacy and does not entail the excessive use of resources. On the other hand, if a proposed intervention is shown to be harmful, it should not be used. Unfortunately, most of the tests and treatments that are available to us in clinical medicine are not so well studied that we know that such clear black-or-white outcomes exist.
With regard to providing intravenous nutrients (parenteral nutrition or protein-sparing therapy), there are a large number of RCTs available from which to begin the decision-making process. Using these data, the recommendations summarized in Table 16 were created. The recommendations range from "A" (should be routinely used) to "E" (should not be used). Both "A" and "B" (probably should be used) are based on the existence of data that established efficacy; a "B" recommendation is made when there was a resource consideration that limits its widespread applicability. A "D" recommendation (probably should not be used) is made when at least 1 RCT is unable to establish efficacy. For those clinical conditions for which no RCTs are available, a "C" recommendation (no data to assist in making a decision) is made. Table 16 were derived from meta-analysis of multiple RCTs); Effect not likely, Ն1 RCT performed and did not demonstrate any change (benefit or harm) in outcome; Effect may or may not be present, RCTs demonstrate conflicting results on outcome; Harm, Ն1 RCT found harmful outcome associated with the use of parenteral nutrition; No RCTs, no RCTs were available to make a recommendation. b PN, intravenous infusion of source of nitrogen (amino acids or protein hydrolysates) and Ն10 kcal ⅐ kg Ϫ1 ⅐ day Ϫ1 nonnitrogenous calories; PST, intravenous infusion of source of nitrogen (amino acids or protein hydrolysates) and Ͻ10 kcal ⅐ kg Ϫ1 ⅐ day Ϫ1 nonnitrogenous calories. c Severe, criteria of Subjective Global Assessment 4 or Nutrition Risk Index, 48 or Ͼ20% weight loss. d Period of time that patient will (or will be expected to) be without enteral nutrient intake. e A, therapy should be used routinely; B, therapy probably should be used; C, no RCT evidence to assess whether or not therapy should be used; D, therapy probably should not be used; E, therapy should not be used routinely. f Data indicated that parenteral nutrition did result in 18% reduction in major postoperative complications, meaning that 35-40 patient-days of therapy required to prevent one such complication; cost versus benefit should be considered. g Mortality may or may not have been favorably influenced by parenteral nutrition provided during the peritransplant period; infection rate was increased as a consequence of the parenteral nutrition. h While no RCTs exist to assist in decision-making process, it should be remembered that, in trials not involving perioperative patients or low-birth-weight infants (a meta-analysis of 18 oncologic trials and a separate meta-analysis of 6 other [alcoholic hepatitis, mild pancreatitis, colitis, AIDS, cystic fibrosis, trauma] trials), parenteral nutrition was associated with an increased risk of infections. i Such infants have very limited nutritional reserves. j No RCTs were identified comparing parenteral nutrition to a control group not receiving any nutritional support; trials comparing parenteral to enteral nutrition indicated that there was a higher mortality in the recipients of the parenteral nutrition. k Performing RCTs in this patient group is not ethical; parenteral nutrition is presumed to be life-saving and sustaining. l One retrospective subgroup analysis of a large RCT assessing perioperative parenteral nutrition indicated that parenteral nutrition was associated with a larger beneficial effect in the severely malnourished patients. m A meta-analysis suggested that branched-chain amino acids, with or without concomitant caloric infusions, were effective in treating hepatic encephalopathy. n The cost of treating with branched-chain amino acids should be weighed against the cost of alternative therapies. o While no RCTs were available to assess protein sparing therapy in most other conditions, the generally disappointing results of the trials of parenteral nutrition should be considered when deciding whether or not to use this form of nutritional treatment. Table 16 is divided into sections. Most of the decisions refer to patients who are not severely malnourished and who will not be deprived of nutrient intake for longer than 2 weeks. (These are the situations for which we have the most data.) Although there are virtually no data to allow us to know with certainty the period of time for which such individuals can tolerate nutrient deprivation, we (R.L.K., T.O.L., and S.K.) agreed that waiting up to 2 weeks in a patient who is not severely malnourished was reasonable. (It must be remembered that this is an "expert opinion," not a data-based conclusion.)
Patients with long-term, or even permanent, gastrointestinal tract insufficiency will, by definition, have nutrient deprivation for more than 2 weeks unless those nutrients are provided intravenously. The recommendation to use, or not to use, parenteral nutrition in any of these individuals rested on his or her anticipated length of survival. Again, it should be appreciated that the 3-month time period is arbitrary; no data either supports or refutes this time selection.
The clinical scenario of being without oral or enteral nutrients for more than 14 days will occasionally arise in patients with severe pancreatitis or inflammatory bowel disease. It will also occur in a few patients in the intensive care unit. We could not unanimously agree as to how far beyond 14 days one could safely wait before the adverse effects of the continued nutrient deprivation would become a problem. Thus, decisions about the period of time beyond 2 weeks when it would be appropriate to use parenteral nutrition in these patients were left to the discretion of individual physicians.
We also had little substantive information from which to create recommendations about how or when to treat severely malnourished individuals. One retrospective subgroup analysis of a large perioperative RCT suggested that parenteral nutrition was associated with a larger beneficial effect in the severely malnourished. Thus, for the most part, these decisions were also left to the judgments of the doctors who were charged with the care of those patients.
We were only able to identify 1 potential benefit from protein-sparing therapy, namely the use of branchedchain amino acids in hepatic encephalopathy. (Even this benefit was more likely a result of an intracerebral metabolic effect than a matter of nitrogen sparing.) Proteinsparing therapy has not been shown to be effective in several clinical conditions (postoperative patients, those with alcoholic hepatitis, low-birth-weight infants who can assimilate nutrients through their gastrointestinal tracts, and individuals with mild pancreatitis). However, it has not been tested in many other diseases. Nonetheless, given its lack of efficacy in the conditions for which it has been tested, as well as the generally disappointing results from RCTs of more intensive parenteral nutrition, it is unlikely that protein-sparing therapy is going to be beneficial in any of the other disease states. 
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